FDA Brief

Warning letters Drugs

FDA warning letter to

Gadget Island, Inc.

High riskIssued Jul 21, 2023Posted Jul 25, 2023Center for Drug Evaluation and Research | CDER

Gadget Island sold three male enhancement products containing undeclared tadalafil and sildenafil without FDA approval.

What happened

FDA reviewed Gadget Island's website from January to July 2023 and obtained samples and labeling of NUX Male Enhancement, DYNAMITE Male Sexual Enhancement, and ProPower Knight Plus 2550mg. Laboratory analyses confirmed each product contained undeclared tadalafil and sildenafil, the active ingredients in Cialis and Viagra. FDA also noted that the firm's websites offered other similarly named products that prior FDA tests found contained undeclared PDE-5 inhibitors.

What FDA found

  1. The three products are unapproved new drugs because they were sold without FDA approval and are not generally recognized as safe and effective for their claimed uses.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. Laboratory tests found undeclared tadalafil and sildenafil, prescription erectile-dysfunction drug ingredients, in all three products.

    FD&C Act sections 502(a) and 502(f)(2), 21 U.S.C. 352(a) and 352(f)(2)
  3. The labels do not give adequate directions for safe use by a layperson, which FDA says is impossible for prescription drugs.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1); 21 CFR 201.5
  4. The labeling is false or misleading because it does not disclose that the products contain prescription erectile-dysfunction drug ingredients.

    FD&C Act sections 502(a) and 201(n), 21 U.S.C. 352(a) and 321(n)
  5. The labeling lacks adequate warnings about serious health risks from the undeclared drug ingredients.

    FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2)
  6. Website and label claims that the products improve erections, ejaculation, and stamina establish that they are intended as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)

What FDA wants

FDA asks Gadget Island to submit a written response within 15 working days of receipt explaining the steps taken to correct the violations and prevent recurrence, with supporting documents; if the firm disagrees, it must include its reasoning and evidence.

Who should pay attention

  • retailers and online sellers of male enhancement supplements
  • brands that sell products labeled as dietary supplements
  • companies sourcing male enhancement products from Gadget Island or similar suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk
  4. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk